Study to evaluate treatment responses to inhaled corticosteroids and to observe cough symptom for a long time period in patients diagnosed with cough variant asthma or eosinophilic bronchitis who is complaining of cough

Not Applicable

• Conditions: Diseases of th respiratory system

• Registration Number: KCT0005679
• Lead Sponsor: Asan Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 January 2021

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

?Adults over 19 years old
?Those presenting with cough that has lasted more than 8 weeks
?Baseline FeNO of 30 ppb or more, suggesting the diagnosis of cough variant asthma and eosinophilic bronchitis
?Those being about to treat with ICS depending on the diagnosis of cough asthma or eosinophilic bronchitis
?Those without symptoms and signs, such as wheezing, dyspnea, heartburn, acid reflux, fever, and purulent sputum, suggesting cough related diseases other than cough variant asthma and eosinophilic bronchitis that require treatment
?Non-smoker for more than 1 month and those not taking ACE inhibitors
?FEV1>80%, FEV1/FVC>70% or more in lung function test within last 1 month
?Those who are considered not to be related to chronic cough by the researcher's decision, even if there are abnormal findings on chest radiography within the last 1 month
?No medication history of steroids and leukotriene receptor antagonists within the last 2 weeks
?No medication history of opiate antitussive drugs such as codeine within the last 1 week

Exclusion Criteria

?Those who cannot use ICS properly
?Those who have a severe cough and require prescription of opioid antitussive drugs such as codeine
?Those who have any physical factors that may affect cough
?Those who are likely to become pregnant within 1 month, plan to become pregnant, or are pregnant

Study & Design

• Study Type: Observational Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The percentage of patients whose cough is improved: Improvement of cough is defined as the case where the Leicester Cough Questionnaire (LCQ) questionnaire score has increased by 1.3 points or more (minimally important difference score) than before treatment.

Secondary Outcome Measures

Name	Time	Method
CQ, Cough Hypersensitivity Questionnaire (CHQ), cough severity Visual Analogue Scale (VAS), cough-related symptoms, and FeNO levels are collected and used to analyze whether they are correlated with FeNO.;Cough is measured by cough VAS and LCQ scores. Patients who are not followed up at outpatient clinics are inquired by telephone survey and LCQ scores are not collected.